Phosphoproteome Profiling of uEVs Reveals p-AQP2 and p-GSK3β as Potential Markers for Diabetic Nephropathy

Author:

Li Qing1,Zhang Jiong2ORCID,Fang Yi1,Dai Yan1,Jia Ping1,Shen Ziyan1,Xu Sujuan3,Ding Xiaoqiang1,Zhou Feng4

Affiliation:

1. Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai 200437, China

2. Department of Nephrology, Sichuan Academy of Sciences & Sichuan Provincial People’s Hospital, Sichuan Clinical Research Center for Kidney Disease, University of Electronic Science and Technology, Chengdu 610072, China

3. Department of Nephrology, The Third Hospital of Hebei Medical University, Shijiazhuang 050051, China

4. Key Laboratory of Carcinogenesis and Cancer Invasion, Liver Cancer Institute, Zhongshan Hospital, Minister of Education, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China

Abstract

Diabetic nephropathy (DN) contributes to increased morbidity and mortality among patients with diabetes and presents a considerable global health challenge. However, reliable biomarkers of DN have not yet been established. Phosphorylated proteins are crucial for disease progression. However, their diagnostic potential remains unexplored. In this study, we used ultra-high-sensitivity quantitative phosphoproteomics to identify phosphoproteins in urinary extracellular vesicles (uEVs) as potential biomarkers of DN. We detected 233 phosphopeptides within the uEVs, with 47 phosphoproteins exhibiting significant alterations in patients with DN compared to those in patients with diabetes. From these phosphoproteins, we selected phosphorylated aquaporin-2 (p-AQP2[S256]) and phosphorylated glycogen synthase kinase-3β (p-GSK3β[Y216]) for validation, as they were significantly overrepresented in pathway analyses and previously implicated in DN pathogenesis. Both phosphoproteins were successfully confirmed through Phos-tag western blotting in uEVs and immunohistochemistry staining in kidney sections, suggesting that phosphoprotein alterations in uEVs reflect corresponding changes within the kidney and their potential as candidate biomarkers for DN. Our research proposes the utilization of phosphoproteins in uEVs as a liquid biopsy, presenting a highly feasible diagnostic tool for kidney disease.

Funder

Shanghai Science and Technology Innovation Action Plan

Shanghai Municipal Key Clinical Specialty

Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai Science and Technology Commission

China National Key R&D Program during the 13th Five-year Plan Period

China National Key R&D Program during the 14th Five-year Plan Period

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Reference44 articles.

1. Targeting inflammation to treat diabetic kidney disease: The road to 2030;Marchant;Kidney Int.,2023

2. Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results;Tong;Diabetes Ther. Res. Treat. Educ. Diabetes Relat. Disord.,2020

3. An autopsy study suggests that diabetic nephropathy is underdiagnosed;Klessens;Kidney Int.,2016

4. Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes;Betz;Kidney Int.,2016

5. Diagnosis of diabetic kidney disease: State of the art and future perspective;Persson;Kidney Int. Suppl. (2011),2018

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3